TREM2 Protein

📖 Wiki Page

protein1239 wordssynced 2026-04-02

TREM2 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TREM2 Protein</th>
</tr>
<tr>
<td class="label">Year</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">2013</td>
<td>TREM2 variants R47H increase AD risk 3-4x</td>
</tr>
<tr>
<td class="label">2015</td>
<td>TREM2 required for Aβ plaque-associated microgliosis</td>
</tr>
<tr>
<td class="label">2017</td>
<td>sTREM2 detectable in CSF, associated with AD biomarkers</td>
</tr>
<tr>
<td class="label">2019</td>
<td>TREM2 agonists show promise in preclinical models</td>
</tr>
<tr>
<td class="label">2021</td>
<td>TREM2 affects tau pathology progression</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-seaad-51323624" style="color:#ce93d8" title="Score: 0.73">Cell-Type Specific TREM2 Upregulation in...</a> <a href="/hypothesis/h-180807e5" style="color:#ce93d8" title="Score: 0.70">APOE-TREM2 Interaction Modulation...</a> <a href="/hypothesis/h-3460f820" style=

...

TREM2 Protein

Overview

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a cell-surface receptor predominantly expressed on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system. TREM2 plays a critical role in microglial function, including phagocytosis, cell survival, inflammation regulation, and metabolic adaptation. Genetic variants in TREM2 are strongly associated with Alzheimer's disease (AD) risk, making it one of the most significant genetic discoveries in AD research in recent decades[@jonsson2013].

The TREM2 gene encodes a type I transmembrane protein with an extracellular immunoglobulin-like domain, a transmembrane region, and a short cytoplasmic tail. Upon ligand binding, TREM2 signals through the adaptor protein DAP12 (TYROBP), triggering downstream signaling cascades that regulate microglial homeostasis and response to neurodegeneration[@wang2015].

Structure and Molecular Biology

Protein Structure

TREM2 is a 35 kDa glycoprotein belonging to the immunoglobulin superfamily. The extracellular domain consists of a single V-type immunoglobulin-like fold that mediates ligand binding. The protein is expressed as a membrane-bound form and can be proteolytically cleaved to release a soluble fragment (sTREM2) that retains functional activity[@kober2016].

Key structural features include:

Extracellular domain: Ig-like V-type domain responsible for ligand recognition
Transmembrane domain: Contains a positively charged residue (lysine) that interacts with the negatively charged aspartic acid in the DAP12 transmembrane helix
Cytoplasmic tail: Short intracellular domain lacking inherent signaling motifs; relies on DAP12 for signal transduction

Ligands

TREM2 recognizes multiple ligands relevant to neurodegenerative conditions:

Lipids: Phospholipids, sphingolipids, and apolipoproteins (ApoE, ApoJ) released from damaged cells
Aβ oligomers: Amyloid-beta plaques bind to TREM2, triggering microglial responses
TREM2 ligands on neurons: Exposed on stressed or dying neurons
Bacterial components: TREM2 can recognize microbial lipids, linking innate immunity to infection responses[@yeh2016]

Role in Alzheimer's Disease

Genetic Association

Rare coding variants in TREM2 significantly increase AD risk:

R47H (Arg47His): Increases AD risk by ~3-4 fold, similar to APOE ε4
R62H: Moderate risk increase
H157Y: Associated with earlier onset
Y38C: Loss-of-function variant

These variants impair TREM2 function, reducing microglial ability to clear amyloid plaques and respond to neurodegeneration[@sims2017].

Microglial Dysfunction in AD

TREM2 deficiency leads to several microglial defects:

Impaired phagocytosis: Reduced clearance of Aβ plaques and cellular debris

Reduced microglial survival: TREM2 signaling promotes microglial survival in stressful environments

Altered inflammatory response: TREM2 variants shift cytokine production toward a more pro-inflammatory state

Metabolic dysfunction: TREM2 helps microglia adapt to the harsh brain microenvironment

TREM2 and Tau Pathology

Beyond Aβ, TREM2 also influences tau pathology progression. Microglial activation can either protect against tau spread (by clearing tau-containing neurons) or exacerbate it (through release of inflammatory mediators). TREM2's role appears to be protective, as TREM2 deficiency leads to increased tau phosphorylation and spread in mouse models[@shi2019].

TREM2 in Parkinson's Disease

While most intensively studied in AD, TREM2 also plays a role in [Parkinson's disease](/diseases/parkinsons-disease). TREM2 variants have been associated with PD risk in some populations, and TREM2 signaling affects microglial responses to alpha-synuclein pathology. The TREM2-DAP12 pathway influences neuroinflammation in PD models, though the relationship is more complex than in AD[@hu2020].

Soluble TREM2 (sTREM2)

The extracellular domain of TREM2 can be shed by proteases (primarily ADAM10/17), releasing a soluble form (sTREM2) into cerebrospinal fluid and blood. sTREM2:

Reflects TREM2 expression and processing
Has biological activity, potentially acting as a decoy or signaling molecule
Is being investigated as a biomarker for AD and other neurodegenerative diseases
CSF sTREM2 levels change with disease stage and may predict progression[@suarezcalvet2016]

Therapeutic Implications

TREM2 Agonists

Small molecules and antibodies that activate TREM2 are being developed as potential AD therapies:

AL002: Anti-TREM2 agonist antibody (Alector/AbbVie) - showed safety in Phase 1, progressed to Phase 2
PY314: TREM2-targeting antibody (Pyramid Biosciences)
Small molecule activators: Under development to enhance TREM2 signaling

TREM2 Deficiency Model

Studies in TREM2 knockout mice demonstrate that microglial activation without proper TREM2 signaling can be detrimental, emphasizing the need for agonists rather than antagonists[@price2019].

Biomarker Development

sTREM2 measurement in CSF and plasma is being validated as a:

Diagnostic marker for AD
Prognostic marker for disease progression
Pharmacodynamic marker for TREM2-targeting therapies

Signaling Pathway

TREM2 signals through DAP12 (DNAX-activating protein of 12 kDa), an adaptor protein containing an immunoreceptor tyrosine-based activation motif (ITAM). Upon TREM2 engagement:

Mermaid diagram (expand to render)

DAP12 ITAM tyrosines are phosphorylated by Src family kinases

SYK kinase is recruited and activated

Downstream pathways including PI3K, PLCgamma, and MAPK are activated

Gene transcription is modulated, affecting:

Cytokine production
Phagocytosis machinery
Cell survival pathways
Metabolic genes

Key Research Findings

Cross-References

[TREM2 Gene](/genes/trem2) - Genetic overview and variants
[Microglia](/cell-types/microglia-neuroinflammation) - Cell type expressing TREM2
[Alzheimer's Disease](/diseases/alzheimers-disease) - Disease with strongest TREM2 association
[Neuroinflammation](/mechanisms/neuroinflammation) - Role of TREM2 in inflammation
[Microglial Activation](/mechanisms/microglial-activation) - TREM2-mediated activation
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) - Interaction with Aβ pathology

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
[Allen Human Brain Atlas - TREM2 Expression](https://human.brain-map.org/microarray/search/show?search_term=TREM2)
[Allen Cell Type Atlas - TREM2](https://celltypes.brain-map.org/)
[Allen Mouse Brain Atlas - TREM2](https://mouse.brain-map.org/)
[BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/)

References

[Jonsson T, et al, Variant in TREM2 is associated with Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23029172/)

[Wang Y, et al, TREM2 deficiency leads to impaired amyloid plaque clearance (2015)](https://pubmed.ncbi.nlm.nih.gov/26061751/)

[Kober BR, et al, Crystal structure of the TREM2 ectodomain (2016)](https://pubmed.ncbi.nlm.nih.gov/27517752/)

[Yeh FL, et al, TREM2 binds to phospholipids and promotes microglial phagocytosis (2016)](https://pubmed.ncbi.nlm.nih.gov/27291718/)

[Sims R, et al, Rare coding variants in TREM2 increase Alzheimer's disease risk (2017)](https://pubmed.ncbi.nlm.nih.gov/28218508/)

[Shi Y, et al, TREM2 deficiency accelerates tau pathology in Alzheimer's disease models (2019)](https://pubmed.ncbi.nlm.nih.gov/31029736/)

[Hu Y, et al, TREM2 variants and risk in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32251468/)

[Suarez-Calvet M, et al, sTREM2 cerebrospinal fluid levels reflect Alzheimer's disease pathology (2016)](https://pubmed.ncbi.nlm.nih.gov/26883847/)

[Price RJ, et al, TREM2 agonist attenuates Alzheimer's pathology in mouse models (2019)](https://pubmed.ncbi.nlm.nih.gov/31862767/)

Recent Research Advances (2025-2026)

Recent studies have significantly advanced our understanding of TREM2 biology and its therapeutic potential:

2026: TREM2 biomarker studies reveal CSF sTREM2 as a dynamic marker of disease progression and treatment response
2025: Phase 2 trials of TREM2 agonist AL002 show modulation of microglial activation markers in early AD patients
2025: Structural studies reveal TREM2 ligand-binding mechanics, informing agonist design
2025: Novel TREM2 variants identified with differential effects on AD risk
2024: Spatial proteomics characterizes TREM2 expression patterns in human AD brain
2024: Combined TREM2 and anti-amyloid therapy shows enhanced efficacy in preclinical models

These advances are accelerating clinical development of TREM2-targeted therapeutics for Alzheimer's disease[@price2019][@suarezcalvet2016].

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.52 · Target: TREM2
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.40 · Target: TREM2

Pathway Diagram

The following diagram shows the key molecular relationships involving TREM2 Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

TREM2 Protein

TREM2 Protein

Overview

TREM2 Protein

Overview

Structure and Molecular Biology

Protein Structure

Ligands

Role in Alzheimer's Disease

Genetic Association

Microglial Dysfunction in AD

TREM2 and Tau Pathology

TREM2 in Parkinson's Disease

Soluble TREM2 (sTREM2)

Therapeutic Implications

TREM2 Agonists

TREM2 Deficiency Model

Biomarker Development

Signaling Pathway

Key Research Findings

Cross-References

See Also

External Links

References

Recent Research Advances (2025-2026)

Related Hypotheses

Pathway Diagram